DNX/BioClin merger to create CRO with $40 mil. in 1995 revenues.
Executive Summary
DNX/BIOCLIN MERGER TO CREATE CRO WITH $40 MIL. IN ANNUAL REVENUES, the contract research organizations announced Aug. 19. DNX generated revenues of $26.5 mil. in 1995 through its pre-clinical drug development services. BioClin generated $14.3 mil. in revenues last year from its Phase I-IV clinical research business. The combined company will have over 300 pharmaceutical clients and 450 employees worldwide.